Leerink Partnrs Predicts Reduced Earnings for Quanterix

Quanterix Co. (NASDAQ:QTRX) – Stock analysts at Leerink Partnrs lowered their FY2024 earnings estimates for shares of Quanterix in a report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.98) per share for the year, down from their previous forecast of ($0.94). The consensus estimate for Quanterix’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Quanterix’s Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.33) EPS and FY2026 earnings at ($0.89) EPS.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Monday, December 23rd. The company reported ($0.22) EPS for the quarter. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%.

Separately, TD Cowen raised their price objective on Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research note on Wednesday, November 13th.

Quanterix Price Performance

Shares of QTRX opened at $10.21 on Thursday. The stock has a 50-day moving average of $11.02 and a 200-day moving average of $12.46. Quanterix has a one year low of $8.21 and a one year high of $29.70. The company has a market cap of $393.29 million, a PE ratio of -9.63 and a beta of 1.33.

Institutional Investors Weigh In On Quanterix

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Janney Capital Management LLC increased its holdings in Quanterix by 40.9% during the 4th quarter. Janney Capital Management LLC now owns 33,192 shares of the company’s stock worth $353,000 after purchasing an additional 9,639 shares in the last quarter. Tallon Kerry Patrick purchased a new position in shares of Quanterix during the fourth quarter valued at approximately $169,000. Graypoint LLC bought a new stake in Quanterix during the fourth quarter worth $691,000. JPMorgan Chase & Co. raised its position in Quanterix by 28.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 217,957 shares of the company’s stock valued at $2,825,000 after buying an additional 47,873 shares during the last quarter. Finally, Exome Asset Management LLC boosted its holdings in Quanterix by 23.2% during the 3rd quarter. Exome Asset Management LLC now owns 73,501 shares of the company’s stock worth $953,000 after acquiring an additional 13,851 shares during the last quarter. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.